A Pérez1, J J Mediavilla2, I Miñambres3, D González-Segura4. 1. Servicio de Endocrinología y Nutrición, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) , Barcelona, España. Electronic address: aperez@santpau.cat. 2. Centro de Salud Burgos Rural Sur, Burgos, España. 3. Servicio de Endocrinología y Nutrición, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España. 4. Departamento Médico Almirall S.A., Barcelona, España.
Abstract
OBJECTIVE: To evaluate the degree of glycemic control in patients with type 2 diabetes in Spain and identify factors associated with glycemic control. PATIENTS AND METHODS: This was a cross-sectional, multicenter, epidemiological study that used consecutive sampling and was conducted in primary care practices in Spain. A total of 5591 patients with type 2 diabetes mellitus lasting more than 1 year and who were treated with hypoglycemic agents for more than 3 months were included in the study. At a single visit, HbA1c levels were measured (A1cNow+ system) and demographic and clinical variables related to diabetes and its treatment were recorded. During the visit, CV risk factors (CVRF), the presence of target-organ damage (TOD), the presence of hypoglycemia and body weight changes within the previous year were recorded. RESULTS: We analyzed data from 5382 patients (mean age 66.7 [10.8] years, mean duration of the diabetes 8.8 [6.3] years). TOD was present in 43.6% of the patients and 59.1% were taking 2 or more drugs. The patients' mean HbA1c was 7.1 (1.1)%, and 48.6% had HbA1c levels <7.0%. The patients with HbA1c levels ≥7.0% had longer-standing diabetes, a higher prevalence of TOD and CVRF, used more complex therapies, experienced more hypoglycemic episodes in the previous year and had more weight gain. In the multivariate analysis, the absence of insulin treatment, the absence of abdominal obesity and atherogenic dyslipidemia, a duration of the diabetes <10 years and an age >70 years were associated with improved glycemic control. CONCLUSIONS: Patients with poorly controlled type 2 diabetes mellitus are highly prevalent in Spain. Factors associated with poorer glycemic control include the complexity of both the disease and the hypoglycemic therapy, a history of hypoglycemia and weight gain.
OBJECTIVE: To evaluate the degree of glycemic control in patients with type 2 diabetes in Spain and identify factors associated with glycemic control. PATIENTS AND METHODS: This was a cross-sectional, multicenter, epidemiological study that used consecutive sampling and was conducted in primary care practices in Spain. A total of 5591 patients with type 2 diabetes mellitus lasting more than 1 year and who were treated with hypoglycemic agents for more than 3 months were included in the study. At a single visit, HbA1c levels were measured (A1cNow+ system) and demographic and clinical variables related to diabetes and its treatment were recorded. During the visit, CV risk factors (CVRF), the presence of target-organ damage (TOD), the presence of hypoglycemia and body weight changes within the previous year were recorded. RESULTS: We analyzed data from 5382 patients (mean age 66.7 [10.8] years, mean duration of the diabetes 8.8 [6.3] years). TOD was present in 43.6% of the patients and 59.1% were taking 2 or more drugs. The patients' mean HbA1c was 7.1 (1.1)%, and 48.6% had HbA1c levels <7.0%. The patients with HbA1c levels ≥7.0% had longer-standing diabetes, a higher prevalence of TOD and CVRF, used more complex therapies, experienced more hypoglycemic episodes in the previous year and had more weight gain. In the multivariate analysis, the absence of insulin treatment, the absence of abdominal obesity and atherogenic dyslipidemia, a duration of the diabetes <10 years and an age >70 years were associated with improved glycemic control. CONCLUSIONS:Patients with poorly controlled type 2 diabetes mellitus are highly prevalent in Spain. Factors associated with poorer glycemic control include the complexity of both the disease and the hypoglycemic therapy, a history of hypoglycemia and weight gain.
Authors: Pedro Mezquita-Raya; Rebeca Reyes-Garcia; Oscar Moreno-Perez; Javier Escalada-San Martin; Miquel Ángel Rubio Herrera; Martin Lopez de la Torre Casares Journal: Diabetes Ther Date: 2015-06-09 Impact factor: 2.945
Authors: Åsne Bakke; John G Cooper; Geir Thue; Svein Skeie; Siri Carlsen; Ingvild Dalen; Karianne Fjeld Løvaas; Tone Vonheim Madsen; Ellen Renate Oord; Tore Julsrud Berg; Tor Claudi; Anh Thi Tran; Bjørn Gjelsvik; Anne Karen Jenum; Sverre Sandberg Journal: BMJ Open Diabetes Res Care Date: 2017-11-08
Authors: Carlos Morillas; Javier Escalada; Rafael Palomares; Diego Bellido; Fernando Gómez-Peralta; Antonio Pérez Journal: Diabetes Ther Date: 2019-07-29 Impact factor: 2.945
Authors: Fernando Gomez-Peralta; José A Fornos Pérez; Ana Molinero; Ignacio M Sánchez Barrancos; Ezequiel Arranz Martínez; Pablo Martínez-Pérez; Inés Mera Gallego; N Floro Andrés-Rodríguez Journal: BMJ Open Diabetes Res Care Date: 2021-11
Authors: Elena Labrador Barba; Marta Rodríguez de Miguel; Antonio Hernández-Mijares; Francisco Javier Alonso-Moreno; Maria Luisa Orera Peña; Susana Aceituno; María José Faus Dader Journal: Patient Prefer Adherence Date: 2017-04-04 Impact factor: 2.711